Arrayjet, the Scottish-based instrumentation company, has won a £150,000 contract with Philip Morris International.

The company’s microarray printing technology will support the tobacco giant’s programme to develop innovative products which have the potential to reduce disease risk in comparison with smoking cigarettes.

Iain McWilliam, chief executive of Arrayjet, said: “PMI’s goal is to provide potentially reduced risk alternatives to smokers who would otherwise continue smoking cigarettes. The company is at the global forefront of this initiative and its scientific research and development program demonstrates its commitment to stringent scientific and global corporate and social responsibility practices. Arrayjet is delighted to provide the means to support this with our microarray printing technology helping to assist its scientific laboratory work.”

Dr. Ashraf Elamin, Manager Proteomics at Philip Morris Products said the Arrayjet solution produced “faster results” adding: “We increased the printing of high throughput of sample analysis whilst significantly optimising quality.”